1532 GMT - Novo Nordisk's American depositary receipts fall sharply after U.S. rival Eli Lilly said an experimental weight-loss pill met its goals in a pivotal study by helping diabetes patients lower blood sugar and even reduce weight. The Danish market is closed Thursday, but Novo Nordisk's ADRs--securities that are effectively a way for U.S. investors to buy stakes in foreign companies--drop 6.9% to $58.51, trading at levels last seen in late 2022, having lost nearly a third of their value since the start of the year. The results are pretty much a best-case scenario for Eli Lilly on weight loss, blood sugar control, tolerability and safety, analysts at Bank of America say in a research note. Eli Lilly shares jump 14%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
April 17, 2025 11:32 ET (15:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。